Sign in
Taking people in United StatesNo phase

The Half Moon Transcatheter Mitral Valve Repair (TMVr) Pilot Study

Key facts

Who runs it
Half Moon Medical
Where
Cleveland, Harrisburg, New York, Portland, and The Bronx, United StatesSee the 5 sites
Trial code
Status
Recruiting
People taking part
30 people, planned
Started
8 Dec 2020
Expected to end
31 Dec 2029
Type of study
Interventional
Treatments tested
  • Half Moon TMVr System
Record updated
12 January 2024

Who can take part

Age
21 years to 95 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (36)Hide the full registry criteria

Who can take part

  • Moderately severe or severe mitral regurgitation (MR Grade ≥ 3+)
  • Symptomatic mitral regurgitation (NYHA Class II-IV), despite guideline-directed medical therapy (GDMT) determined by the local multidisciplinary heart team
  • Deemed, by the local multidisciplinary heart team, to be at high risk for mitral valve surgery and not appropriate for commercially approved transcatheter mitral valve therapies
  • Age ≥ 21
  • Native mitral valve geometry and size compatible with the Half Moon TMVr implant
  • Anatomy suitable for transfemoral transseptal access with the Half Moon TMVr System
  • Willing to sign Informed Consent for participation in the study and return for all required post-procedure follow-up visits

Who cannot take part

  • Prior transseptal intervention with occlusion device currently implanted
  • Prior mitral valve surgery or endovascular procedure, or need for other valve surgery/procedure
  • Any endovascular therapeutic interventional or surgical procedure performed within 30 days prior to enrollment
  • Prior stroke, TIA, or myocardial infarction within 90 days
  • Need for emergent surgery
  • Pregnant, nursing or planning to be pregnant. (Female participants of childbearing potential must have a negative pregnancy test prior to enrollment)
  • Currently participating in an investigational drug or another device study that has not yet reached its primary endpoint
  • Pulmonary hypertension with resting pulmonary artery systolic pressures ≥ 2/3 systemic systolic pressure
  • Right-sided congestive heart failure with echocardiographic evidence of severe right ventricular dysfunction
  • Severe Chronic Obstructive Pulmonary Disease (COPD) demonstrated by Forced Expiratory Volume (FEV1) < 750cc
  • GI bleeding within 6 months
  • History of bleeding diathesis or coagulopathy or patient will refuse blood transfusion
  • Active infections requiring current antibiotic therapy (if temporary illness, patients may enroll 2 weeks after discontinuation of antibiotics)
  • Known hypersensitivity or contraindication to study or procedure medications/contrast which cannot be adequately managed medically
  • Left ventricular ejection fraction (LVEF) < 25%, or LVEF 25-30% in the presence of left ventricular end diastolic volume index (LVEDVi) >120mL/m2 as measured by resting echocardiogram within 30 days of the Index Procedure
  • Platelet count of <75,000 cells/mm3
  • Renal insufficiency (Creatinine > 2.5 mg/dL)
  • Implanted with venous stents (iliac and femoral) including inferior vena cava (IVC) filter or congenital abnormalities of the IVC that would preclude ability for transfemoral access with the delivery system
  • Evidence of intracardiac, inferior vena cava, or femoral venous mass, thrombus, or vegetation
  • Prohibitive mitral annular or leaflet calcification
  • Diseased mitral anterior leaflet such as flail or prolapse
  • Left ventricular end diastolic diameter (LVEDD) > 75mm
  • Severe tricuspid regurgitation
  • Need for coronary revascularization
  • Severe symptomatic carotid artery stenosis
  • Endocarditis within 6 months
  • Subject is unwilling or unable to adhere to the protocol recommended anticoagulation treatment
  • Hemodynamic instability requiring dependency on either inotropic agents or mechanical circulatory support
  • Contraindication to transesophageal echocardiography (TEE)

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Mitral valve insufficiency

This trial is currently available in United States.

  • University Hospitals Cleveland Medical Center*Cleveland, United StatesContact: Guilherme Attizzani, MDTaking people
  • UPMC Heart & Vascular InstituteHarrisburg, United StatesContact: Hemal Gada, MDTaking people
  • Columbia University Medical Center/ NewYork Presbyterian HospitalNew York, United StatesContact: Susheel Kodali, MDTaking people
  • Oregon Health Science UniversityPortland, United StatesContact: Firas Zahr, MDTaking people
  • Montefiore Medical CenterThe Bronx, United StatesContact: Azeem Latib, MDTaking people

About the trial

What the trial wants to find out

The study is a prospective, multi-center, single-arm, non-randomized, Early Feasibility Study (EFS) to evaluate the safety and performance of the Half Moon TMVr System in patients with severe, symptomatic mitral regurgitation, who are at high risk for conventional mitral valve surgery.

The group in the trial

  • Half Moon TMVr SystemTreatment being tested

    The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of the Safety and Performance of the Half Moon Transcatheter Mitral Valve Repair System in High Risk Patients With Severe, Symptomatic Mitral Regurgitation
Criteria questions
Built from NCT04343313, who can take part
Record updated
12 January 2024